More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Abstract Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients' quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment versus placebo or dupilumab among patients with m...
Saved in:
Main Authors: | Andrew Blauvelt (Author), Kilian Eyerich (Author), Alan D. Irvine (Author), Marjolein de Bruin-Weller (Author), Shawn G. Kwatra (Author), Melinda Gooderham (Author), Brian Kim (Author), Brian M. Calimlim (Author), Wan-Ju Lee (Author), Eliza M. Raymundo (Author), Yingyi Liu (Author), Sarah Ofori (Author), Andrew M. Platt (Author), Jonathan I. Silverberg (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
by: Shawn G. Kwatra, et al.
Published: (2024) -
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
by: April W. Armstrong, et al.
Published: (2024) -
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
by: Eric L. Simpson, et al.
Published: (2024) -
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
by: Nina Magnolo, et al.
Published: (2024) -
Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)